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Abstract 
Novel analogs of the allosteric, biased PAR1 ligand ML161 (parmodulin 2, PM2) were prepared in order to 
identify potential anti-thrombotic and anti-inflammatory compounds of the parmodulin class with improved 
properties. Investigations of structure-activity relationships of the western portion of the 1,3-diaminobenzene 
scaffold were performed using an intracellular calcium mobilization assay with endothelial cells, and several 
heterocycles were identified that inhibited PAR1 at sub-micromolar concentrations. The oxazole NRD-21 was 
profiled in additional detail, and it was confirmed to act as a selective, reversible, negative allosteric modulator 
of PAR1. In addition to inhibiting human platelet aggregation, it showed superior anti-inflammatory activity to 
ML161 in a qPCR assay measuring the expression of tissue factor in response to the cytokine TNF-alpha in 
endothelial cells. Additionally, NRD-21 is much more plasma stable than ML161, and is a promising lead 




aPC: activated Protein C; Boc: tert-butoxycarbonyl; DCE: 1,2-dichloroethane; DCM: dichloromethane; DIC: 
disseminated intravascular coagulation; DIPEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; 
DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;  
FDA: U.S. Food and Drug Administration; GPCR: G protein coupled receptor; HATU: hexafluorophosphate 
azabenzotriazole tetramethyl uranium; HOBt: 1-hydroxybenzotriazole; HTS: high-throughput screening; HUVEC: 
human umbilical vein endothelial cells; IC50: half-maximal inhibitory concentration; iCa2+: intracellular calcium 
mobilization; LC-MS: liquid chromatography-mass spectrometry; MI: myocardial infarction; NMR: nuclear 
magnetic resonance; PAR: protease-activated receptor; qPCR: quantitative polymerase chain reaction; SAR: 
structure-activity relationship; SEM: standard error of the mean; TF: tissue factor; TLC: thin layer 
chromatography; TNF-α: Tumor Necrosis Factor-alpha 
Keywords 
Parmodulin, NRD-21, ML161, PAR1, Allosteric inhibitor, Oxazole, Anti-platelet, Antithrombotic, Anti-
inflammatory, Biased ligand 
1. Introduction 
The use of biased ligands for G protein coupled receptors (GPCRs) has emerged as a promising strategy for 
maximizing therapeutic signals mediated by GPCRs, while potentially mitigating undesired side effects linked to 
alternative signaling pathways initiated by the same receptors. Protease-activated receptors (PARs) are GPCRs 
that are activated by a variety of vascular proteases that cleave the N-termini of PARs, revealing a tethered 
peptide that activates the receptor1 and initiates a plethora of signals.2 PARs are present in a variety of tissues 
and are implicated in a variety of pathologies including thrombosis, inflammation, and cancer cell metastasis.3, 4 
The varied phenotypic effects of PAR activation have recently been connected to the activation of specific G-
proteins and arrestins,5 and biased signals have been observed with proteases such as activated protein C (aPC) 
that cleave PAR N-termini at alternative sites.6, 7, 8, 9, 10 Synthetic peptides11, 12 and peptidomimetics13, 14 
based on PAR tethered ligands have also shown biased signaling by blocking or activating only a subset of 
signals. Pepducins, a novel class of fatty acid-tethered peptides modeled after intracellular GPCR loops 
developed by Kuliopulos and coworkers,15, 16, 17 have been reported to act as biased antagonists at PAR2.4, 18 
Previously, we reported that small molecules identified via high-throughput screening (HTS) are capable of 
inhibiting platelet granule secretion, while permitting the shape change of platelets normally observed upon 
platelet activation via PAR1 agonism, thus acting as “biased antagonists” of PAR1.19, 20 Our collaborators 
(Flaumenhaft and coworkers) have accrued evidence that these small molecules, termed parmodulins, act at the 
intracellular side of PAR1 to block signaling mediated by Gq, but not G12/13.21, 22 The parmodulin ML161 (1, 
also referred to as parmodulin 2 or PM2, Figure 1) was found to promote cytoprotective and anti-inflammatory 
effects in endothelium in a manner similar to aPC,22 and as with aPC it was highly effective at minimizing 
necrosis of coronary tissue in a mouse model of myocardial infarction (MI).23 We also recently confirmed that 
ML161 and its aniline analog RR-90 are selective, reversible, and allosteric inhibitors (negative allosteric 
modulators) of PAR1 signaling via the G protein Gq.24 The presence of PAR1 is required for the cytoprotective 
effects of aPC25 and ML16121, 22 in endothelium, and targeting PAR1 with parmodulins to inhibit pro-
inflammatory or pro-thrombotic signals while activating beneficial anti-inflammatory and/or cytoprotective 
signals could be an effective therapeutic strategy for sepsis, stroke, and thrombosis. This manuscript describes 
our efforts to more deeply explore structure–activity relationships (SARs) at the western side of parmodulins 




Figure 1. Previous parmodulins and their performance in a platelet P-selectin assay.20 
 
ML161 was previously assigned as a Molecular Libraries probe,20, 26 and was our most potent analog to date in 
the P-selectin assay, a flow cytometry assay which measures levels of P-selectin on the surface of activated 
platelets. Our interest in measuring the effects of parmodulins in endothelial cells led us to develop a protocol 
for an intramolecular calcium mobilization (iCa2+) assay using adherent EA.hy926 cells in 96 well plates.24 Both 
responses are driven by PAR1 Gq, but the endothelial calcium assay also offers higher throughput and lower 
variability than the platelet P-selectin assay, so we have utilized it as our primary assay for ongoing studies. 
Compounds were screened in 96 well plates at a concentration of 10 μM, using the PAR1 tethered ligand 
peptide TFLLRN-NH2 (5 μM) as agonist. 7-point concentration–response curves were obtained for compounds 
demonstrating > 70% inhibition in this screen, which was an arbitrary cutoff. 
 
A significant liability of ML161 is its low stability in mouse plasma. The branched amide 2 was equipotent to 
ML161 in the platelet P-selectin assay, but showed greatly improved stability in mouse plasma after 5 h (65% 
remaining vs 2%), presumably due to increased resistance to protease-catalyzed hydrolysis.20 Unfortunately, 2 
possesses decreased solubility in water with 1% DMSO (9 μM vs 58 μM for 1),20 and mediocre inhibition in the 
endothelial iCa2+ assay (Table 1).24 Therefore, we focused our efforts on finding alternative analogs that could 
offer equal or better potency than ML161 in the iCa2+ assay but with improved plasma stability, which is 
particularly important for longer duration in vivo experiments. 
 
Table 1. SAR of simple alkyl analogs.  
Cmpd;  Structure iCa2+ assay %Inhib;  Cmpd;  Structure iCa2+ assay %Inhib;  







































   
 
6.7 ± 0.2 
a. Assays were performed with adherent EA.hy926 endothelial cells according to the protocol reported in the 
Supporting Info. % Inhibition was measured at 10 μM with 5 μM TFLLRN-NH2 and n = 4 wells, unless 
otherwise noted, with standard error of the mean (SEM) provided. pIC50s (–logIC50s) were estimated from 
curves fitted to measurements on 3 separate wells for each concentration, using 4-variable non-linear 
regression in GraphPad Prism v. 6. The detailed assay protocol was previously described.24 
b. IC50 is undefined– a double sigmoidal concentration–response curve was not obtained. 
c. In platelet P-selectin assay.20 
d. n = 3. 
2. Results 
This manuscript describes our SAR studies with modifications to the “western” end of the scaffold. Many of 
these analogs, including the most promising analogs identified herein, could be prepared via simple acylation 
reactions of aniline precursors (Scheme 1). The eastern 2-bromobenzamide of ML161 that was optimized 
previously was fixed at this stage, though other eastern benzene substitutions are also tolerated. 
 
Scheme 1. General conditions for the synthesis of western amide analogs. 
 
 
Following up on our previous modifications at the western side exemplified by 1 and 2, we explored the role of 
branching and chain length (Table 1). The cyclopentyl analog 3 showed moderate inhibition, but increasing 
further the level of substitution at the alpha position (6) greatly increased plasma stability but decreased 
inhibition greatly in the platelet P-selectin assay.20 The acyclic analog 7 also showed weak efficacy in the iCa2+ 
assay. Compound 8, with one carbon less than ML161, also showed decreased activity, but interestingly its more 
lipophilic trifluoromethyl analog 9 showed increased potency (IC50 = 0.38 µM) compared to 8 and similar activity 
to ML161. Alternatively, extension of the carbon chain of ML161 by one led to decreased efficacy and/or 
potency (compounds 10 and 11), which is consistent with what we observed previously with platelets.20 A close 
analog of the previously-reported reverse amide 4 (Figure 1) was also prepared (12), and showed very good 
potency (IC50 = 0.22 μM), but only moderate efficacy (∼50% maximal inhibition). Such reverse amides could 
address potential liabilities associated with toxic anilide or aniline hydrolysis products. 
 
Introduction of polar functional groups was performed in order to improve the potency and drug-like properties 
of 1 and 2 (Table 2). Addition of hydroxy or methoxy groups (compounds 13–18) led to significant losses of 
efficacy. Malonate derivatives (19–21) also showed weak efficacy. Two carbamates were synthesized (22 and 
23), with 23 showing moderate activity (60% inhibition at 10 μM), as did ether 24. 
 
Table 2. SAR of neutral or acidic analogs.  
Cmpd;  Structure iCa2+ assay %Inhib;  Cmpd;  Structure iCa2+ assay %Inhib;  































a. Assays were performed with adherent EA.hy926 endothelial cells according to the protocol reported in the 
Supporting Info. % Inhibition was measured at 10 μM with 5 μM TFLLRN-NH2 and n = 4 wells, unless 
otherwise noted, with standard error of the mean (SEM) provided. pIC50s (–logIC50s) were estimated from 
curves fitted to measurements on 3 separate wells for each concentration, using 4-variable non-linear 
regression in GraphPad Prism v. 6. The detailed assay protocol was previously described.24 
 
Continuing with more basic amine functionality (Table 3), we found that incorporation of a dimethylamine unit 
at the western end (25) led to a complete loss of activity. However, as previously reported,20, 24 the aniline RR-
90 (5) showed very good activity and similar potency to ML161. The tertiary aniline 26 showed weak activity, as 
did the aniline 27 with a terminal ether. Preparation of the more basic analog 28 also led to a steep drop in 
efficacy. Interestingly, the anilines 29 and 30 both showed evidence of activation, rather than inhibition, of 
PAR1. Aniline 29 was synthesized via a reductive amination reaction with the aniline precursor S3 (Scheme 1) 
and cyclopentenone, and 30 was prepared by cyclization of the same precursor with 1,4-dibromobutane (see 
Supplementary data for details). Aniline 30 (KMK-17) is presently under investigation as a potential positive 
allosteric modulator of PAR1. 
 
Table 3. SAR of amine analogs.  
Cmpd;  Structure iCa2+ assay %Inhib;  Cmpd;  Structure iCa2+ assay %Inhib;  
ID#  pIC50a ID#  pIC50a 
25 
 
3 ± 3% 28  17 ± 6% 
VAK-11 
  























   
a. Assays were performed with adherent EA.hy926 endothelial cells according to the protocol reported in the 
Supporting Info. % Inhibition was measured at 10 μM with 5 μM TFLLRN-NH2 and n = 4 wells, unless 
otherwise noted, with standard error of the mean (SEM) provided. pIC50s (–logIC50s) were estimated from 
curves fitted to measurements on 3 separate wells for each concentration, using 4-variable non-linear 
regression in GraphPad Prism v. 6. The detailed assay protocol was previously described.24 bn = 3. 
 
Next, we explored heterocyclic amide analogs (Table 4). The exploration of western pyrrolidine derivatives (31–
34) initially yielded differences in activity between the R- and S-enantiomers in both the Boc-protected 
pyrrolidines (31, 33) and the deprotected derivatives (32, 34). However, re-synthesis and retesting of 31–34 to 
obtain concentration–response curves did not show significant inhibition of calcium mobilization by the PAR1 
agonist TFLLRN-NH2. 
 
Table 4. SAR of heterocyclic amide analogs.  
Cmpd;  Structure iCa2+ assay %Inhib;  Cmpd;  Structure iCa2+ assay %Inhib;  


































    
  
a. Assays were performed with adherent EA.hy926 endothelial cells according to the protocol reported in the 
Supporting Info. % Inhibition was measured at 10 μM with 5 μM TFLLRN-NH2 and n = 4 wells, unless 
otherwise noted, with standard error of the mean (SEM) provided. pIC50s (–logIC50s) were estimated from 
curves fitted to measurements on 3 separate wells for each concentration, using 4-variable non-linear 
regression in GraphPad Prism v. 6. The detailed assay protocol was previously described.24 bThese 
compounds were resynthesized and retested and were found to be inactive when 7-point concentration–
response curves were obtained. 
 
The furan 35 showed a high level of inhibition (92%, IC50 = 0.32 μM), which prompted us to explore other 
oxygen-containing heterocycles, particularly since monosubstituted furans such 35 may suffer from undesirable 
oxidative metabolism. The tetrahydrofurans 36 and 37 showed only modest inhibition, but the oxazoles 38 and 
39 showed very good inhibition. The phenyl analog 40 can be considered as a control compound, and it 
displayed moderate inhibition (58%). 
 
The potent oxazoles 38 (NRD-21) and 39 (NRD-23) were profiled further, along with the trifluoromethyl analog 9 
(NRD-25) and the furan 35 (VAK-7) (Figure 2). Concentration-response curves were obtained in our intracellular 
calcium mobilization assay. All four analogs showed similar potencies (IC50 = 0.32 to 0.42 µM), though 
interestingly the oxazole 38 showed much better efficacy than 39, which only inhibited calcium activity at ∼ 50% 
at the highest concentration (31.6 µM). 
 
 
Figure 2. Concentration-response curves for PAR1 antagonists in the TFLLRN-NH2-mediated (5 µM) iCa2+ 
mobilization assay with EA.hy926 cells: A) 35 (VAK-7), B) 39 (NRD-23), C) 9 (NRD-25), D) 38 (NRD-21). 
 
Our previous studies showed the lead compound ML161 (1) and aniline 5 to have selective and reversible 
activity towards PAR1. We endeavored to determine if our novel analogs possess the same properties. 
Selectivity for PAR1 was conducted with our calcium mobilization assay and PAR1 or PAR2 agonists (Figure 3). 
EA.hy926 cells were dosed with either vorapaxar at 0.316 µM or the selected parmodulin at 10 µM. The cells 
were then stimulated using either the PAR1 agonist TFLLRN-NH2 or the PAR2 agonist SLIGKV-NH2 at 3.16 µM. All 
parmodulins and vorapaxar showed inhibition of the PAR1 receptor (Figure 3A). Consistent with Table 4, oxazole 
39 (NRD-23) was the only parmodulin that showed<75% inhibition of PAR1, while all other parmodulins and 
vorapaxar exhibited > 75% inhibition (<25% stimulation) (Figure 3A). All antagonists tested with the PAR2 
agonist SLIGKV-NH2 showed no inhibition of PAR2 (Figure 3B), therefore we conclude that all analogs are highly 
selective for PAR1 over PAR2. 
 
 
Figure 3. Selectivity data of antagonists in A) PAR1 (TFLLRN-NH2)- and B) PAR2 (SLIGKV-NH2)-driven iCa2+ 
mobilization. Parmodulins were used at 10 µM; vorapaxar was used at 0.316 µM. PAR1 agonist TFLLRN-NH2 and 
PAR2 agonist SLIGKV-NH2 were used at 3.16 µM; Vehicle (V) = 10% DMSO/water. 
 
We also conducted “wash” studies where the endothelial cells were treated with select inhibitors, then washed 
twice with buffer prior to addition of the agonist and measurement of intracellular calcium levels (Figure 4). 
Parmodulins were compared to vorapaxar, which is a known poorly reversible orthosteric inhibitor of PAR1. As 
expected, all parmodulins tested had a significant loss of inhibition after washing, while vorapaxar remained 
unaffected, confirming that they inhibit PAR1 in a reversible manner. 
 
 
Figure 4. Reversibility studies of the PAR1 antagonist vorapaxar and selected parmodulins. Parmodulins were 
used at 10 µM; vorapaxar was used at 0.316 µM. PAR1 agonist TFLLRN-NH2 and PAR2 agonist SLIGKV-NH2 were 
used at 3.16 µM; Vehicle (V) = 10% DMSO/water. Cells containing antagonist were washed with buffer prior to 
the treatment with PAR1 agonist TFLLRN-NH2 (5 µM). 
 
Out of the four parmodulins profiled, compound 38 (NRD-21) was selected for further studies; we reasoned that 
the trifluoromethyl analog 9, though potent, likely possesses the same plasma stability and solubility liabilities as 
ML161. ML161 was characterized as a negative allosteric modulator in both platelets and endothelial cells in our 
previous studies, and we reasoned that the structurally similar NRD-21 would act in a similar manner. Indeed, 
increasing concentrations of antagonist 38 led to a reduction in efficacy of the PAR1 agonist TFLLRN-NH2 (Figure 
5). The reduction of maximum efficacy (“ceiling effect”) of the PAR1 agonist in the presence of NRD-21, rather 
than the simple rightward shift in concentration–response curves, is consistent with the action of NRD-21 as a 
negative allosteric modulator of TFLLRN-NH2 at PAR1, rather than a simple competitive inhibition. We previously 
reported this phenomenon with ML161.20, 24 Interestingly the drop in maximal efficacy is not as pronounced 
for NRD-21 as for the aniline 5 (RR-90), which we previously described.24 
 
 
Figure 5. iCa2+ concentration–response of the PAR1 agonist TFLLRN-NH2 in the presence of increasing 
concentrations of NRD-21. 
 
Next, an assay was performed to measure the ability of NRD-21 to inhibit platelet aggregation. PAR1 is highly 
expressed in platelets, and its activation leads to aggregation and coagulation. The platelet aggregation assay 
was performed with ML161 and NRD-21 (Figure 6). In both cases, human washed platelets were incubated with 
parmodulins at 10 µM, then the PAR1/2 agonist SFLLRN-NH2 (1.5 µM) was added. Complete inhibition of platelet 
aggregation by both ML161 and NRD-21 was observed. 
 
 
Figure 6. Human platelet aggregation assay of A) ML161 (10 µM, red trace) and B) NRD-21 (10 µM, red trace) in 
the presence of the PAR1/2 agonist SFLLRN-NH2 (1.5 µM). Blue traces = DMSO. 
 
The anti-inflammatory and cytoprotective effects reported for ML16121, 22, 23 begged the question if other 
structurally related parmodulins also share these effects. To this end, we performed a qPCR assay measuring the 
expression of tissue factor (TF) in endothelial cells (HUVEC) in response to the inflammatory cytokine Tumor 
Necrosis Factor-alpha (TNF-α). TF has been long established to mediate the pro-inflammatory and pro-coagulant 
effects27 of TNF-α28, 29 and endotoxins,30 and unnatural TF expression is therefore the driver of disseminated 
intravascular coagulation (DIC) observed under conditions of cancer or sepsis.31 We measured the level of TF 
mRNA 4 h after treatment with ML161 or NRD-21 followed by the addition of TNF-α (Figure 7). Pretreatment 
with ML161 (column 4) blocked the ∼3-fold increase in TF expression caused by TNF-α alone (column 1), and 
NRD-21 was even more efficacious, dropping TF RNA levels to below baseline levels. The mechanism of this 




Figure 7. qPCR assay (n = 3) measuring the inhibition of TNF-α (25 ng/mL) induced TF expression in HUVEC after 
treatment with ML161 and NRD-21 (10 µM). Inhibitors were added at t = 0, TNF-α was added at t = 1 h, and 
mRNA was measured at t = 4 h. Data was analyzed with one-way ANOVA followed by Bonferroni's multiple 
comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
With these promising results in hand with NRD-21, we measured its stability and a number of parameters 
relevant to its use as an in vivo probe (Table 5). Importantly, NRD-21 is much more plasma stable than ML161. 
After 4 h in mouse plasma, 32% of NRD-21 remained, while ML161 was <1%. Improved stability in human 
plasma was also observed for NRD-21 (97% vs 79% after 4 h), as shown in Figure 8. As with ML161, NRD-21 also 
shows excellent stability in the presence of human liver microsomes, with no apparent degradation after 1 h. It 
also shows no measurable toxicity in a human cell line (hepG2). An area for improvement remains the low 
solubility of the current lead compounds of this class, with a solubility of 17 μM for NRD-21 in a kinetic aqueous 
solubility assay with 2.5% DMSO. Both compounds were also profiled for off-target receptor binding by the 
Psychoactive Drug Screening Program (PDSP).32 Both modified radioligand binding to 3 or 4 different targets, 
including inhibition of binding to the peripheral benzodiazepine receptor (PBR) and activation of the serotonin 
transporter (SERT). 
 
Table 5. Comparison of ML161 and NRD-21.   
ML161 NRD-21 




Plasma stability <1% (4 h, mouse) 79% (4 h, human) 32% (4 h, mouse) 97% (4 h, human) 
Microsomal stability 99% (1 h, human) 99% (1 h, human) 
Kinetic aqueous solubility 
(2.5% DMSO) 
24 μM 17 μM 
PAR2 activity? None observed None observed 
Off-target effectsb 4: Beta1 = 49%; Beta3 = 32%; 
PBR = 84%; SERT = –44% 
3: 5HT-5A = –31%; NET = 31%; 
PBR = 67%; SERT = –44% 
Cytotoxicity (CC50) (human 
hepG2 cells) 
>150 μM >150 μM 
Reversible? Yes Yes 
a. Average of independent assays, each with IC50s determined from curve fits with n = 3. See e.g. Table 1 
for more details. bFraction of off-targets for which there is >20% inhibition (at 10 μM concentration) of 
41 targets from the Psychoactive Drug Screening Program. bNumber of off-targets (out of 44) for which 
there is >30% inhibition or activation of standard radioligand binding (at 10 μM concentration) of 44 
targets from the Abbreviations of target names with mean % inhibition of binding are given. 5HT = 5-
hydroxytryptamine receptor; Beta = β-adrenoceptor; NET = norepinephrine transporter; 
PBR = peripheral benzodiazepine receptor (rat); SERT = serotonin transporter. Off-target assays were 
performed by the National Institute of Health Psychoactive Drug Screening Program (PDSP). 
 
 
Figure 8. Human plasma stability of ML161 (left) and NRD-21 (right). Points indicate the natural logarithm of the 
average of 3 replicates at each time point. 
3. Discussion 
Our SAR studies at the western end of the 1,3-diaminobenzene scaffold have determined that lipophilic groups 
of limited size are best able to inhibit PAR1-driven Gq signaling. However, some heteroatom functionality is 
tolerated, with western heterocycles giving the most promising profiles. The oxazole NRD-21 was identified as a 
compound with slightly improved potency over our previous lead compound ML161, but with much improved 
plasma stability, making it more suitable for in vivo studies. 
 
Most notably, NRD-21 is highly efficacious in the inhibition of TNF-α-mediated TF expression in endothelium, 
making it a promising lead within this new class of parmodulin anti-inflammatory agents. The signaling 
pathway(s) leading to the anti-inflammatory effects of the parmodulins is not fully understood, but Flaumenhaft 
has published evidence consistent with a PAR1-mediated (via Gβγ) signaling pathway that ultimately drives 
transcriptional responses.22 Conversely, the FDA-approved orthosteric PAR1 antagonist vorapaxar has shown 
deleterious effects in cultured endothelium, including increased levels of apoptosis and decreased barrier 
integrity.21 We have also demonstrated, here and previously,21, 24 that unlike vorapaxar, parmodulins are 
readily reversible inhibitors of PAR1, which is an important safety consideration for anti-thrombotic agents. 
NRD-21 also inhibited human platelet aggregation similarly to ML161. We conclude that the parmodulin class of 
intracellular allosteric ligands of PAR1, exemplified by NRD-21 with its 1,3-diaminobenzene scaffold, is promising 
for both anti-thrombotic and anti-inflammatory-related indications. Efforts are ongoing to identify additional 
potent parmodulins, characterize their signaling pathway(s), and further investigate their utility in thrombosis 
and inflammation-related and proliferative disorders. 
4. Experimental section 
4.1. General synthetic information 
All reagents and solvents, including anhydrous solvents, were purchased from commercial vendors and used as 
received. Deionized water was purified by charcoal filtration to a minimum resistance of 15 MΩ and used for 
reaction workups and in reactions with water. NMR spectra were recorded on Varian 300 MHz or 400 MHz 
spectrometers as indicated. Proton and carbon chemical shifts are reported in parts per million (ppm; δ) relative 
to tetramethylsilane (1H δ 0), or CDCl3 (13C δ 77.16), (CD3)2CO (1H δ 2.05, 13C δ 29.84), d6-DMSO (1H δ 2.50, 13C δ 
39.5), or CD3OD (1H δ 3.31, 13C δ 49.00). NMR data are reported as follows: chemical shifts, multiplicity 
(obs = obscured, app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
comp = complex overlapping signals); coupling constant(s) in Hz; integration. Unless otherwise indicated, NMR 
data were collected at 25 °C. Filtration was performed by vacuum using VWR Grade 413 filter paper, unless 
otherwise noted. Flash chromatography was performed using Biotage SNAP cartridges filled with 40–60 µm 
silica gel on Biotage Isolera automated chromatography systems with photodiode array UV detectors. Analytical 
thin layer chromatography (TLC) was performed on Agela Technologies 0.25 mm glass plates with 0.25 mm silica 
gel. Visualization was accomplished with UV light (254 nm) and KMnO4 stain, unless otherwise noted. Chemical 
names were generated and select chemical properties were calculated using either ChemAxon Marvin suite or 
ChemDraw Professional 15.1. NMR data were processed using either MestreNova or ACD/NMR Processor 
Academic Edition using the JOC report format. High-resolution mass spectra (HRMS) were obtained from the 
University of Cincinnati Environmental Analysis Service Center using an Agilent 6540 Accurate-Mass LC-MS with 
Q-TOF. 
 
4.2. LC-MS characterization methods 
Tandem liquid chromatography/mass spectrometry (LC-MS) was performed on a Shimadzu LCMS-2020 with 
autosampler, photodiode array detector, and single-quadrupole MS with ESI and APCI dual ionization using a 
Peak Scientific nitrogen generator. 
 
4.2.1. Method A 
Column: Phenomenex Gemini C18 (100 × 4.6 mm, 3 µm particle size, 110 Å pore size) 
 
Column temperature: 40 °C 
 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeOH w/ 0.1% formic acid 
 
Flow Rate: 1.0 mL/min 
 
Gradient: 0 to 0.1 min: 25% MeOH (Isocratic) 
0.1 min to 5 min: 25% to 95% MeOH (Gradient) 
5 min to 7 min: 95% MeOH (Isocratic) 
 
4.2.2. Method B 
Column: Phenomenex Gemini C18 (100 × 4.6 mm, 3 µm particle size, 110 Å pore size) 
 
Column temperature: 40 °C 
 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic acid 
 
Flow Rate: 1.0 mL/min 
 
Gradient: 0 to 0.1 min: 50% MeCN (Isocratic) 
0.1 min to 5 min: 50% to 95% MeCN (Gradient) 
5 min to 7 min: 95% MeCN (Isocratic) 
 
4.2.3. Method C 
Column: Phenomenex Gemini C18 (100 × 4.6 mm, 3 µm particle size, 110 Å pore size) 
 
Column temperature: 40 °C 
 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic acid 
 
Flow Rate: 1.0 mL/min 
 
Gradient: 0 to 0.5 min: 50% MeCN (Isocratic) 
0.5 min to 4 min: 50% to 95% MeCN (Gradient) 
4 min to 6.3 min: 95% MeCN (Isocratic) 
 
4.3. General procedures for synthesis of parmodulins via amide coupling. 
4.3.1. Method A: Amide coupling using EDC 
To a round bottom flask with stir bar under nitrogen were added the appropriate carboxylic acid and anhydrous 
DCM/DMF (85:15; 0.2–0.6 M). The amine HCl salt to be coupled (1.2 eq.), HOBt (1.2 eq.), EDC-HCl (1.2 eq.), and 
DIPEA (2.1 eq.) were added and the reaction was stirred under nitrogen until complete, as measured by TLC 
and/or LC-MS. The reaction was diluted with DCM, washed with saturated aq. NaHCO3, 1 M aq. HCl, and brine, 
then dried over Na2SO4, filtered, and concentrated under reduced pressure prior to purification by flash 
chromatography (SiO2). The following parmodulins were synthesized utilizing this method: 3, 6, 8, 9, 13, 17, 25, 
and 35. 
 
4.3.2. Method B: Conversion to the acid chloride and subsequent acylation 
To an oven-dried round bottom flask with stir bar under nitrogen were added the carboxylic acid, dry DCM, and 
3 Å molecular sieves. Oxalyl chloride (1.2 eq.) and a catalytic amount of DMF (1–2 mol %) were added and the 
reaction was stirred while attached to a bubbler (to monitor production of CO2) at 20 °C for 2–3 h. The amine 
HCl salt (1 eq.) in DCM and DIPEA (2 eq.) were added and the reaction was stirred under nitrogen for 3–6 h. The 
reaction was diluted with EtOAc and washed with half-saturated aq. NaHCO3, 1 M HCl (30 mL), and brine, then 
dried over Na2SO4, filtered, and concentrated under reduced pressure prior to purification by flash 
chromatography (SiO2). The following parmodulins were synthesized utilizing this method: 7, 11, 18, and 36–40. 
 
4.3.3. Method C: Acylation 
To an oven-dried round bottom flask with stir bar and under nitrogen were added the acid chloride, dry DCM, 
and 3 Å molecular sieves. The amine HCl salt (1 eq.) in DCM and DIPEA (2 eq.) were added and the reaction was 
stirred under nitrogen for 3–6 h. The reaction was diluted with EtOAc and washed with half-saturated aq. 
NaHCO3, 1 M HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give 
crude product. The following parmodulins were synthesized utilizing this method: 10, 12, 19, and 24. 
 
4.3.4. Method D: Amide coupling using HATU 
To a round bottom flask with stir bar under nitrogen was added the carboxylic acid and anhydrous DCM. The 
amine (1.2 eq.), HATU (1.2 eq.), and DIPEA (1.2 eq.) were added and the reaction was stirred under nitrogen. 
The reaction was diluted with DCM (75 mL) and washed with saturated NaHCO3, 1 M HCl (30 mL), brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure to give crude material. The following 
parmodulins were synthesized utilizing this method: 14–16, 31, and 33. 
 
4.4. Preparation of N-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-5-carboxamide (38, 
NRD-21, Scheme S1) 
To a vial with a magnetic stir bar was added aniline S3 (50.2 mg, 0.173 mmol), oxazole-5-carboxylic acid (27 µL, 
0.347 mmol), EDC-HCl (33.9 mg, 0.177 mmol), and HOBt (26.7 mg, 0.174). The vial was sealed and flushed with 
nitrogen for 5 min., then DCE (1.5 mL) and DMF (0.5 mL) were added. To the resulting solution was added a 10% 
solution of pyridine in DCE (0.14 mL, 0.173 mmol) by syringe, and the reaction was stirred for 24 h. A sample 
aliquot was taken from the reaction, concentrated under reduced pressure, dissolved in a minimal amount of 
HPLC grade MeCN, and analyzed by LC-MS to confirm reaction completion. The reaction was then diluted with 
EtOAc (30 mL) and washed with half-saturated aq. NaHCO3 (3 × 15 mL), brine (2 × 10 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The crude product was dissolved in a minimal amount of 
DCM, loaded onto a 10 g silica gel column, and purified by flash chromatography (MeOH:DCM, 0–8%) to give 38 
as a yellow oil (40 mg, 60%). TLC: mobile phase: MeOH:DCM (6:94), Rf = 0.30; LC-MS tR = 4.29 min. 
(Characterization Method A); m/z = 387.29 (M + H); 1H NMR (300 MHz, CD3OD) δ = 8.36 (s, 1H), 8.15 (t, 
J = 2.0 Hz, 1H), 7.85 (s, 1H), 7.64 (dd, J = 1.0, 7.9 Hz, 1H), 7.53–7.41 (m, 5H), 7.41–7.28 (m, 3H); 13C NMR 
(100 MHz, CD3OD) δ = 169.1, 157.2, 154.7, 147.0, 140.2, 140.1, 139.3, 134.2, 132.3, 131.2, 130.2, 129.8, 128.7, 
120.5, 118.5, 118.1, 114.4. HRMS (ESI+) calculated for C17H12BrN3O3 (M + H) 386.0135, found 386.0147. 
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AcOH   acetic acid 
aPC   activated protein C 
conc.  concentrated 
Boc   tert-butoxycarbonyl (protecting group) 
DCE   1,2-dichloroethane (solvent) 
DCM   dichloromethane (solvent) 
DIC   disseminated intravascular coagulation 
DMAP   4-dimethylaminopyridine (nucleophilic catalyst) 
DMF   N,N-dimethylformamide (solvent) 
DMSO   dimethylsulfoxide (solvent) 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (amide coupling reagent) 
DIPEA  N,N-diisopropylethylamine (base) 
EtOAc   ethyl acetate (solvent) 
FBS   fetal bovine serum 
GFP   green fluorescent protein 
GPCR   G-protein coupled receptor 
HATU   1-[bis(dimethylamine)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (amide coupling reagent) 
HBSS   Hank’s balanced salt solution 
HEPES   4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (buffering agent) 
HOBt   1-hydroxybenzotriazole (additive for amide coupling) 
HPLC   high performance liquid chromatography 
HTS   high-throughput screening 
HUVEC   human umbilical vein cells 
iCa2+   intracellular calcium mobilization 
IC50   half-maximal inhibitory concentration 
IPA   isopropyl alcohol 
LCMS   liquid chromatography-mass spectrometry 
NMR   nuclear magnetic resonance 
MI   myocardial infarction 
MeCN   acetonitrile (solvent) 
PAR   protease-activated receptor 
Pd/C   palladium on carbon (charcoal) 
PGE1   prostaglandin E1 
Phe   phenylalanine 
PRP   platelet-rich plasma 
SAR   structure-activity relationship 
SEM   standard error of the mean 
TEA   triethylamine (base) 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran (solvent) 
TNF-α   Tumor Necrosis Factor-alpha 
 
2. Assay protocols 
a) Intracellular calcium mobilization assay 
All assays, including washing studies, were run according to our previously published protocol.1  
 
b) Platelet aggregation assay 
Tyrode’s buffer preparation: 
137 mM NaCl 4 g 
20 mM HEPES 2.6 g 
13.8 mM NaHCO3 0.58 g 
2.5 mM KCl 0.093 g 
0.36 mM NaH2PO4 0.0216 g 
 500 mL pH 7.4 
 
Just before use, 0.25% BSA and 0.1% glucose were added. 
 
Human platelet-rich plasma (PRP) preparation:  
Whole blood (10 mL) was collected from a volunteer. The blood was diluted with an equal volume of Tyrode’s 
buffer (10 mL) and then transferred into two 17x100 mm tubes and 50 ng/mL of PGE1 (final concentration) was 
added. The samples were centrifuged in a Beckman GS-6 at 200 g (1700 rpm) for 7 minutes at room 
temperature. After completion, the PRP was removed and transferred to a new set of 17x100 tubes, then 2 mM 
EDTA (final concertation) and 40 uL per 10 mL of 0.5 M EDTA were added. The cells were again centrifuged at 
700 g (1700 rpm) for 10 minutes at room temperature. The platelet cells were resuspended in Tyrode’s buffer 
containing 50 ng/mL PGE1 and 2 mM EDTA. A small aliquot of platelet cells was taken for cell counting with a Scil 
Vet ABC Hematology Analyzer. After counting, the suspension was centrifuged at 700 g (1700 rpm) for 10 min. at 
room temperature, and then resuspended in Tyrode’s buffer at 1 X 108 cells per mL.  
 
Platelet aggregation:  
Platelet aggregation was measured using a whole-blood lumi-aggregometer (Chrono-Log).  Platelet cells in 
Tyrode’s buffer (300 µL) were transferred to a siliconized glass cuvette at 37 °C with constant stirring at 1000 
rpm. The cells were dosed with a parmodulin (10 µM final concentration) and incubated for 2 min. The agonist 
SFLLRN-NH2 (1.5 µM final concentration) was then added to the cuvette and response was monitored for five 
minutes after the addition of the agonist. 
 
c) Tissue Factor gene expression assay 
EA.hy926 cells were seeded on a 12 well plate and treated with the parmodulins ML161 (10 µM) and NRD-21(10 
µM) for 4 hours. Some wells received TNF-α (25 ng/mL) 1 h after the addition of parmodulins. At the end of the 
4 h experiment, cells were washed with PBS, and total RNA was extracted using TRIzol (Life Technologies, 
Carlsbad, CA). RNA was reverse transcribed into cDNA using the QuantiTect® Reverse transcription kit (Qiagen), 
and the levels of tissue factor (TF) gene expression was quantified by Quantitative PCR reactions using TaqMan, 
consisting of 5 µL TaqMan Fast Advanced Master Mix (Applied Biosystems), 0.5 µL each of TF and GAPDH 
TaqMan primers/probes (final concentrations of 900 nM/250 nM, respectively), and 20–30 ng of genomic DNA 
(1 µL) in a 20 µL reaction. Thermal cycling conditions were as follows: 1 cycle of 95 °C for 10 min., followed by 50 
cycles of 95 °C for 10 s and 60 °C for 20 s. Real-time PCR primer/probes were purchased from Integrated DNA 
Technologies (Coralville, IA). TF Primers: forward 5’-ACCCGTCAATCAAGTCTACAC-3’; Reverse 5’-
GTCTGCTTCACATCCTTCACA-3’. GAPDH Primers: forward 5’- GGATTTGGTCGTATTGGG-3’; Reverse 5’- 
GGAAGATGGTGATGGGATT-3’  
 
Data was analyzed with one-way ANOVA followed by Bonferroni's multiple comparisons test. *P<0.05 **P<0.01, 
***P<0.001, ****P<0.0001.  
 
d) Plasma stability protocol 
Solid NRD-21 and ML-161 were dissolved in dimethyl sulfoxide (DMSO) to give 1 mM solutions. Human plasma 
was incubated for 30 min at 37 °C prior to the addition of each of the compounds. NRD-21 and ML-161 solutions 
were added to 490 µL and 495 µL aliquots of plasma to final concentrations of 20 µM and 10 µM respectively. 
Three replicates for each compound were incubated for 24 h at 37°C. 50 µL aliquots of each sample were 
collected and quenched in 100 µL of methanol stored on ice at seven time points of 0 min, 30 min, 1 h, 2 h, 4 h, 
8 h, and 24 h. Samples were vortexed and centrifuged at 12,000 rpm. The supernatant was collected and loaded 
on a 0.2 µm nylon filter plate for vacuum filtration. 50 µL of the filtrate was diluted in 100 µL of methanol 




3. Synthetic procedures 
a) General information 
All reagents and solvents, including anhydrous solvents, were purchased from commercial vendors and used as 
received. Deionized water was purified by charcoal filtration to a minimum resistance of 15 MΩ and used for 
reaction workups and in reactions with water. NMR spectra were recorded on Varian 300 MHz or 400 MHz 
spectrometers as indicated. Proton and carbon chemical shifts are reported in parts per million (ppm; δ) relative 
to tetramethylsilane (1H δ 0), or CDCl3 (13C δ 77.16), (CD3)2CO (1H δ 2.05, 13C δ 29.84), d6-DMSO (1H δ 2.50, 
13C δ 39.5), or CD3OD (1H δ 3.31, 13C δ 49.00). NMR data are reported as follows: chemical shifts, multiplicity 
(obs = obscured, app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, comp 
= complex overlapping signals); coupling constant(s) in Hz; integration.  Unless otherwise indicated, NMR data 
were collected at 25 °C. Filtration was performed by vacuum using VWR Grade 413 filter paper, unless otherwise 
noted. Flash chromatography was performed using Biotage SNAP cartridges filled with 40-60 µm silica gel on 
Biotage Isolera automated chromatography systems with photodiode array UV detectors. Analytical thin layer 
chromatography (TLC) was performed on Agela Technologies 0.25 mm glass plates with 0.25 mm silica gel. 
Visualization was accomplished with UV light (254 nm) and KMnO4 stain, unless otherwise noted. Chemical 
names were generated and select chemical properties were calculated using either ChemAxon Marvin suite or 
ChemDraw Professional 15.1. NMR data were processed using either MestreNova or ACD/NMR Processor 
Academic Edition using the JOC report format. High-resolution mass spectra (HRMS) were obtained from the 
University of Cincinnati Environmental Analysis Service Center using an Agilent 6540 Accurate-Mass LC-MS with 
Q-TOF. 
 
b) LC-MS characterization methods 
Tandem liquid chromatography/mass spectrometry (LC-MS) was performed on a Shimadzu LCMS-2020 with 
autosampler, photodiode array detector, and single-quadrupole MS with ESI and APCI dual ionization using a 
Peak Scientific nitrogen generator.  
 
Method A  
Column:    Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size)  
Column temperature:   40 °C  
Sample Injection:   1–5 µL of sample in MeCN or MeOH  
Chromatographic monitoring:  UV absorbance at 210 or 254 nm  
Mobile Phase:    Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeOH w/ 0.1% formic acid  
Flow Rate:    1.0 mL/min 
Gradient:    0 to 0.1 min: 25% MeOH (Isocratic)  
0.1 min to 5 min: 25% to 95% MeOH (Gradient)  
5 min to 7 min: 95% MeOH (Isocratic)  
 
Method B 
Column:    Phenomenex Gemini C18 (100 x 4.6 mm, 3 μm particle size, 110 Å pore size) 
Column temperature:   40 °C 
Sample Injection:   1–5 μL of sample in MeCN or MeOH 
Chromatographic monitoring:  UV absorbance at 210 or 254 nm 
Mobile Phase:    Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic acid 
Flow Rate:    1.0 mL/min 
Gradient:    0 to 0.1 min: 50% MeCN (Isocratic) 
0.1 min to 5 min: 50% to 95% MeCN (Gradient) 
5 min to 7 min: 95% MeCN (Isocratic) 
 
Method C 
Column:  Phenomenex Gemini C18 (100 x 4.6 mm, 3 μm particle size, 110 Å pore size) 
Column temperature:  40 °C 
Sample Injection: 1–5 μL of sample in MeCN or MeOH 
Chromatographic monitoring:  UV absorbance at 210 or 254 nm 
Mobile Phase:  Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic acid 
Flow Rate:  1.0 mL/min 
Gradient:  0 to 0.5 min: 50% MeCN (Isocratic) 
0.5 min to 4 min: 50% to 95% MeCN (Gradient) 
4 min to 6.3 min: 95% MeCN (Isocratic) 
 
c) Preparative HPLC purification methods 
Preparative liquid chromatography was performed on a Shimadzu LC-20AP preparative HPLC with autosampler, 
dual wavelength detector, and fraction collector. 
 
Method A 
Column:  Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 μm particle 
size, 110 Å pore size) 
Mobile Phase:  Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeOH w/ 0.1% formic acid 
Peak collection:  measured by UV absorbance at 210 or 254 nm 
Sample Injection:  0.1–1.9 mL (2 mL sample loop) of sample in DMSO 
Flow Rate:  6.0 mL/min 
Gradient:  0 to 1.5 min: 25% MeOH 
1.5 min to 8 min: 25% to 95% MeOH 
8 min to 10.5 min: 95% MeOH 
 
Method B 
Column:  Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 μm particle 
size, 110 Å pore size) 
Mobile Phase:  Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic acid 
Peak collection:  measured by UV absorbance at 210 or 254 nm 
Sample Injection:  0.1–1.9 mL (2 mL sample loop) of sample in DMSO 
Flow Rate:  6.0 mL/min 
Gradient:  0 to 1.5 min: 25% MeCN 
1.5 min to 8 min: 25% to 95% MeCN 
8 min to 10.5 min: 95% MeCN 
 
d) Synthetic schemes 
Scheme S1. Synthesis of oxazole NRD-21 
 
 
Scheme S2. Synthesis of butoxyphenylether TY-13 
 
 
Scheme S3. Synthesis of methyl carbamate VAK-9 
 
 
Scheme S4. Synthesis of ethyl carbamate VAK-10 
 
 
Scheme S5. Synthesis of secondary amine DG-75 
 
 
Scheme S6. Synthesis of pyrrolidine analog KMK-17 
 
 
e) Experimental procedures for select parmodulins 
 
2-bromo-N-(3-nitrophenyl)benzamide (S2) 
S2 was synthesized according to a previously published protocol.2 
 
 
N-(3-aminophenyl)-2-bromobenzamide hydrochloride (S3) 
To a round bottom flask with stir bar was added a solution of SnCl2•2H2O (6.15 g, 0.03 mol) in conc. HCl (5 mL).  
To this solution was added a solution of 2-bromo-N-(3-nitrophenyl)benzamide (S2, 1.75 g, 0.01 mol) in ethanol 
(50 mL), and the resulting suspension was stirred at 55 °C for 2 h.  A sample aliquot was taken from the reaction, 
basified with 2M aq. NaOH, filtered, and the filtrate was concentrated under reduced pressure, dissolved in a 
minimal amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The reaction 
was cooled to 20 °C, basified with 2 M aq. NaOH (until pH 9), and filtered. The filtrate was concentrated under 
reduced pressure to half volume and then extracted with DCM (150 mL). The organic layer was washed with 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude product. The crude 
material was dissolved in DCM and added to 0.9 M HCl in ether (20 mL) and stirred for 5 min. at 20 °C to form a 
precipitate. The precipitate was filtered, washed with DCM, collected, and dried to give aniline HCl salt S3 (1.6 g, 




1 was synthesized according to a previously published protocol.2 
 
 
2-bromo-N-[3-(3-methylbutanamido)phenyl]benzamide (2)  




3 was synthesized according to a previously published protocol.2 
 
 
3-(2-chlorobenzamido)-N-propylbenzamide (4)  








Analogue (7) was synthesized by coupling S3 with 2-methylbutanoyl chloride (59 mg, 0.489 mmol) according to 
general method B. The crude material was dissolved in a minimal amount of DCM, loaded onto a 10 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–47%) to give 7 as a white solid (80 mg) in 44% 
yield. LC/MS tR = 5.57 min (Characterization Method A); m/z = 375.00 (M + H); 1H NMR (400 MHz, (CD3)2CO) δ 
= 9.54 (br. s., 1 H), 9.22 (br. s., 1 H), 8.16 (br. s., 1 H), 7.72 - 7.20 (m, 7 H), 2.51 - 2.38 (m, 1 H), 1.78 - 1.64 (m, 1 




Analogue (9) was synthesized by coupling S3 with 3,3,3-trifluoropropanoic acid (15 µL, 0.170 mmol) according to 
general method A. The crude material was dissolved in a minimal amount of DCM, loaded onto a 5 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–80%) to give 9 as a yellow oil (19 mg) in 28% 
yield. LC/MS tR = 4.93 min (Characterization Method A); m/z = 402.70 (M + H); 1H NMR (300 MHz, CD3OD) δ = 




To an oven-dried round bottom flask with stir bar under nitrogen were added 3-nitrobenzoic acid (1 g, 5.98 
mmol), dry DCM, and 3Å molecular sieves. Oxalyl chloride (1.2 eq.) and a catalytic amount of DMF (1 mol %) 
were added and the reaction was stirred while attached to a bubbler (to monitor production of CO2) at 20 °C for 
2 h. propylamine (1 eq.) in DCM and DIPEA (2 eq.) were added and the reaction was stirred under nitrogen for 
23 h. The reaction was diluted with EtOAc and washed with half-saturated aqueous NaHCO3, 1M HCl (30 mL), 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give S4 (1 g) as a beige solid in 
83% yield. The material was pushed forward without purification. LC/MS tR = 6.88 min (Characterization Method 
A); m/z = 209.70 (M + H); 1H NMR (400MHz, CDCl3)  δ = 8.55 (t, J = 1.9 Hz, 1 H), 8.21 - 8.15 (m, 1 H), 8.12 (td, J = 
1.2, 7.8 Hz, 1 H), 7.77 (t, J = 5.4 Hz, 1 H), 7.49 (t, J = 8.0 Hz, 1 H), 3.39 - 3.28 (m, 2 H), 1.57 (sxt, J = 7.3 Hz, 2 H), 




A solution of S4 (940 mg, 4.51 mmol) in EtOH (20 mL) was flushed with nitrogen for 5 min. To a 250 mL round 
bottom hydrogenator flask under nitrogen was suspended 10% Pd/C (240 mg, 0.226 mmol) in EtOH/H2O (4:1) 
and the resultant suspension was added to the solution of S4. The flask was attached to the hydrogenator and 
the reaction was purged with H2 gas for 2 min. The reaction was left to stir at room temperature under 25 bar of 
H2 for 1 h, after which an aliquot was taken from the reaction, filtered through celite and cotton, and 
concentrated under reduced pressure. The aliquot was used for LCMS monitoring which showed reaction 
completion. The reaction was filtered through a funnel packed with Celite. The filter cake was washed with 
MeOH and the filtrate was concentrated under reduced pressure. The free-amine was dissolved in DCM and 
added to 0.6 M HCl in ether (20 mL) to give S5 (900 mg) as a clear yellow oil in 93% yield. The material was 
pushed forward without purification. LC/MS tR = 3.84 min (Characterization Method A); m/z = 178.85 (M + H); 
13C NMR (75 MHz, CD3OD) δ = 166.8, 136.6, 131.3, 130.1, 127.0, 125.6, 122.0, 41.5, 22.3, 10.4. 
 
 
3-(2-bromobenzamido)-N-propylbenzamide (12)  
Analogue (9) was synthesized by acylating S5 with 2-bromobenzoyl chloride (53 µL, 0.408 mmol) according to 
general method C. The crude material was dissolved in a minimal amount of DCM, loaded onto a 25 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–50%) to give 12 as a white solid (26 mg) in 
23% yield. LC/MS tR = 5.41 min (Characterization Method A); m/z = 384.80 (M + Na); 1H NMR (400 MHz, CD3OD) 
δ = 8.11 (s, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.69 (d, J = 8.0 Hz, 1 H), 7.61 - 7.50 (m, 2 H), 7.50 - 7.36 (m, 3 H), 3.34 (t, 




Analogue (13) was synthesized by coupling S3 with 3-methoxypropanoic acid (16 µL, 0.174 mmol) according to 
general method A. The crude material was dissolved in a minimal amount of DCM, loaded onto a 5 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–50%) to give 13 as a white solid (26 mg) in 
40% yield. LC/MS tR = 4.36 min (Characterization Method A); m/z = 478.70 (M + H); 1H NMR (300 MHz, CD3OD) 
δ = 7.99 (t, J = 1.9 Hz, 1 H), 7.67 (dd, J = 0.9, 8.0 Hz, 1 H), 7.54 - 7.42 (m, 2 H), 7.42 - 7.34 (m, 3 H), 7.29 (q, J = 1.0 




To an oven-dried round bottom flask with stir bar under nitrogen were added [(2S)-2-
hydroxybutanoyl]oxysodium (50 mg, 0.40 mmol), PyBOP (210 mg, 0.40 mmol), and anhydrous DCE (4.0 mL). The 
resulting solution was stirred for 10 min at room temperature before aniline S3 (100 mg, 0.34 mmol) and DIPEA 
(60 µL, 0.35 mmol) were added. The reaction was heated at 45 ºC for 48 h. After 48 h, a small aliquot was taken 
from the reaction, concentrated under reduced pressure, dissolved in minimal amount of HPLC grade MeCN, 
and  analyzed with LCMS to confirm reaction completion. The reaction was diluted with DCM (10 mL), washed 
with saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under vacuum to give 
crude material which dissolved in minimal DCM, loaded on to a 10 g silica column, and purified by flash 
chromatography (EtOAc:hexanes 0–100%) to give 25 mg of 14 in 19% yield. LC/MS tR = 5.54 min 
(Characterization Method A); m/z = 400.75 (M + Na); 1H NMR (300 MHz, CD3OD) δ = 7.95 (t, J = 2.1 Hz, 1H), 7.66 
(dd, J = 8.0, 1.1 Hz, 1H), 7.53-7.42 (m, 4H), 7.39-7.28 (m, 2H), 4.09 (dd, J = 7.3, 4.2 Hz, 1H), 1.92-1.84 (m, 1H), 




To an oven-dried round bottom flask with stir bar under nitrogen were added [(2R)-2-hydroxy-3-methyl-
butanoic acid (39 mg, 0.33 mmol), PyBOP (160 mg, 0.31 mmol), and anhydrous DCE (3.0 mL). The resulting 
solution was stirred for 10 min at room temperature before aniline S3 (75.0 mg, 0.34 mmol) and DIPEA (50 µL, 
0.29 mmol) were added. The reaction was heated at 45 ºC for 48 h. After 48 h, a small aliquot was taken from 
the reaction, concentrated under reduced pressure, dissolved in minimal amount of HPLC grade MeCN, and 
analyzed with LCMS to confirm reaction completion. The reaction was diluted with DCM (10 mL), washed with 
saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under vacuum to afford crude 
material which was purified using preparative HPLC (MeOH:H2O with 0.1% formic acid, 50-95%) to give 8 mg of 
15 in 8% yield. LC/MS tR = 5.43 min (Characterization Method A); m/z = 414.75 (M + Na); 1H NMR (300 MHz, 
CD3OD) δ = 8.99 (br. s., 1H), 7.92–7.88 (m, 1H), 7.69–7.30 (m, 8H), 4.05–4.02 (m, 1H), 3.47–3.38 (m, 1H), 2.27–




To an oven-dried round bottom flask with stir bar under nitrogen were added [(2S)-2-hydroxy-3-methyl-butanoic 
acid (39 mg, 0.33 mmol), PyBOP (160 mg, 0.31 mmol), and anhydrous DCE (3.0 mL). The resulting solution was 
stirred for 10 min at room temperature before aniline S3 (75.0 mg, 0.34 mmol) and DIPEA (50 µL, 0.29 mmol) 
were added. The reaction was heated at 45 ºC for 48 h. After 48 h, a small aliquot was taken from the reaction, 
concentrated under reduced pressure, dissolved in minimal amount of HPLC grade MeCN, and analyzed with 
LCMS to confirm reaction completion. The reaction was diluted with DCM (10 mL), washed with saturated 
aqueous NaHCO3, brine, dried over Na2SO4, filtered, and concentrated under vacuum to afford crude material 
which was purified using preparative HPLC (MeOH:H2O with 0.1% formic acid, 50-95%) to give 9 mg of 16 in 9% 
yield. LC/MS tR = 5.44 min (Characterization Method A); m/z = 414.75 (M + Na); 1H NMR (300 MHz, CD3OD) δ = 
7.97 (t, J = 2.0 Hz, 1H), 7.67 (dd, J = 8.0, 1.1 Hz, 1H), 7.54–7.29 (m, 6H), 3.97 (d, J = 3.8 Hz, 1H), 2.22–2.12 (m, 1H), 




Analogue (17) was synthesized via a peptide coupling between S3 (50.0 mg, 0.172 mmol) and methoxyacetic 
acid (23.2 mg, 0.258 mmol) according to general method A. The crude material was dissolved in a minimal 
amount of DCM, loaded onto a 10 g silica column, and purified by flash chromatography (MeOH:DCM, 0-10%) to 
give 17 as a yellow oil (46 mg) in 73% yield. LC/MS tR = 4.39 min (Characterization Method A); m/z = 362.70 (M + 
H); 1H NMR (300 MHz, CDCl3) δ 8.00 (t, J = 1.9 Hz, 1H), 7.68 (dd, J = 7.9, 0.9 Hz, 1H), 7.54-7.29 (m, 7 H), 4.04 (s, 




Analogue (18) was synthesized by acylating S3 with 2-methoxypropanoyl chloride (35.0 mg, 0.286 mmol) 
according to general method C. The crude material was dissolved in a minimal amount of DCM, loaded onto a 10 
g silica column, and purified by flash chromatography (EtOAc:hexanes, 0–60%) to give 18 as a white solid (36 
mg) in 33% yield. LC/MS tR = 5.20 min (Characterization Method A); m/z = 400.75 (M + Na); 1H NMR (400 MHz, 
CDCl3) δ = 8.43 (br. s, 1 H), 8.04 (br. s, 1 H), 7.99 (t, J = 2.0 Hz, 1 H), 7.61 (dd, J = 1.1, 7.9 Hz, 1 H), 7.57 (dd, J = 1.8, 
7.6 Hz, 1 H), 7.47 - 7.40 (m, 2 H), 7.38 (dt, J = 1.2, 7.5 Hz, 1 H), 7.34 - 7.27 (m, 2 H), 3.79 (q, J = 6.8 Hz, 1 H), 3.46 
(s, 3 H), 1.42 (d, J = 6.8 Hz, 3 H). 
 
 
methyl 2-{[3-(2-bromobenzamido)phenyl]carbamoyl}acetate (19) 
Analogue (19) was synthesized by acylating S3 with methyl 3-chloro-3-oxo-propanoate (120 μL, 1.12 
mmol)according to general method C.The crude material was dissolved in a minimal amount of DCM, loaded 
onto a 10 g silica column, and purified by flash chromatography (EtOAc:hexanes, 0–80%) to give 19as a pale 
yellow solid(100 mg) in 26% yield.1H NMR (300MHz,CDCl3) δ= 9.30 (s, 1 H), 8.38 (s, 1 H), 7.87 (s, 1 H), 7.59 -7.43 
(m, 3 H), 7.35 -7.26 (m, 2 H), 7.24 -7.19 (m, 1 H), 3.71 (s, 3 H), 3.36 (s, 2 H). 
 
 
2-{[3-(2-bromobenzamido)phenyl]carbamoyl}acetic acid (20)  
To a 25 mL round bottom flask with a stir bar was added 19 (23.0 mg, 0.0588 mmol) and THF (4 mL) and H2O (2 
mL). LiOH (3 mg, 0.134 mmol) was added and the reaction was stirred for 1 h at room temperature. The reaction 
was diluted with EtOAc (15 mL) and washed with 1 M HCl (15 mL). The layers were separated, and a second 
extraction was performed on the aqueous layer with EtOAc (15 mL). The organic layers were combined and 
washed with brine (2X 10 mL), dried over with NaSO4, filtered, and concentrated under reduced pressure to give 
the desired product 20 as a light brown solid (20 mg) in 90% yield. 1H NMR (300 MHz, CD3OD) δ = 8.01 (d, J = 1.3 
Hz, 1 H), 7.68 (d, J = 8.0 Hz, 1 H), 7.56 - 7.44 (m, 2 H), 7.44 - 7.37 (m, 3 H), 7.36 - 7.25 (m, 1 H), 3.46 (s, 2 H). 
 
 
N'-[3-(2-bromobenzamido)phenyl]propanediamide (21)  
To a 20 mL scintillation vial with a stir bar was added 19 (25.0 mg, 0.0639 mmol) and via syringe was added THF 
(0.5 mL) and 7 N NH4OH (1 mL), respectively. The reaction solvent was removed under reduced pressure to give 
the crude product. The product was dissolved in a minimal amount of DMSO, and loaded onto a 12 g C18 
column, and purified via reverse phase chromatography (MeOH:water, 0-100%) to give product 21 as a white 
crystalline solid (10 mg) in 42% yield. 1H NMR (300 MHz, CD3OD) δ = 8.02 - 7.96 (m, 1 H), 7.67 (dd, J = 1.1, 8.0 
Hz, 1 H), 7.54 - 7.45 (m, 2 H), 7.44 - 7.36 (m, 3 H), 7.35 - 7.25 (m, 1 H), 3.37 (s, 2 H). 
 
 
methyl N-[3-(2-bromobenzamido)phenyl]carbamate (22)  
To an oven-dried round bottom flask with stir bar under nitrogen were added aniline S3 (50 mg, 0.172 mmol), 
anhydrous DCE, and TEA (23.9 µL, 0.172 mmol). The vessel was flushed with nitrogen gas for an additional 5 min 
and then methyl chloroformate (13 µL, 0.172 mmol) was added and the reaction was allowed to stir at room 
temperature for 48 h. A sample aliquot was taken from the reaction, concentrated under reduced pressure, 
dissolved in a minimal amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion.  
The reaction was diluted with EtOAc and washed with half-saturated aqueous NaHCO3, 1M HCl (30 mL), brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude material which was 
dissolved in a minimal amount of DCM, loaded onto a 10 g silica column, and purified by flash chromatography 
(MeOH:DCM, 0–4%) to give 22 as a colorless oil (15 mg) in 25% yield. LC/MS tR = 4.70 min (Characterization 
Method A); m/z = 350.65 (M + H). 1H NMR (400 MHz, CD3OD) δ 7.87–7.85 (m, 1H), 7.68 (ddd, J = 8.0, 1.2, 0.4 Hz, 
1H), 7.52 (ddd, J = 7.6, 1.9, 0.4 Hz, 1H), 7.47 (td, J = 7.5, 1.2 Hz, 1H), 7.38 (ddd, J = 8.0, 7.3, 1.9 Hz, 1H), 7.33–7.25 
(m, 3H), 3.74 (s, 3H). 
 
 
ethyl N-[3-(2-bromobenzamido)phenyl]carbamate (23) 
To an oven-dried round bottom flask with stir bar under nitrogen were added aniline S3 (50 mg, 0.172 mmol), 
anhydrous DCE, and TEA (23.9 µL, 0.172 mmol). The vessel was flushed with nitrogen gas for an additional 5 min 




To a round bottom flask with stir bar under nitrogen were added 3-nitrophenol (500 mg, 3.59 mmol), 60% NaH 
in mineral oil (0.154 mL, 5.39 mmol), and DMF (6 mL). The flask was flushed with nitrogen for an additional 5 
min and 1-bromobutane (0.466 mL, 4.31 mmol) was syringed into the vessel. The reaction was stirred under 
nitrogen overnight at 125 °C. A small aliquot of the reaction was taken and monitored via TLC which showed 
consumption of starting material and formation of desired product. The reaction was diluted with EtOAc (30 mL) 
and transferred to a 500 mL separatory funnel. The organic layer was washed with water (3x 20mL) and then 
collected in an Erlenmeyer flask and dried with sodium sulfate. The dry organic solvent was transferred to a pre-
weighed round bottom flask, concentrated down on the rotovap and placed on the hi-vac overnight to give S6 
(692 mg) as a clear oil in 99% yield. The material was pushed forward without purification. This compound has 
been previously reported and characterized (CAS#122329-01-5). TLC: mobile phase: EtOAc:hexanes (25:75), Rf: 
0.9; 1H NMR (400 MHz, CDCl3) δ = 7.80 (td, J = 0.9, 8.2 Hz, 1 H), 7.71 (t, J = 1.0 Hz, 1 H), 7.41 (t, J = 8.2 Hz, 1 H), 





A solution of S6 (692 mg, 3.54 mmol) in MeOH (5 mL) was flushed with nitrogen for 5 min. To a 50 mL round 
bottom flask under nitrogen was suspended 10% Pd/C (197 mg, 3.54 mmol) in MeOH/H2O (4:1) and the 
resultant suspension was added to the solution of S6. A balloon was filled with H2 gas and inserted into the flask 
and the reaction was purged with H2 gas for 2 min. The reaction was left to stir under a full balloon of H2 for 1 h, 
after which an aliquot was taken from the reaction, filtered through celite and cotton, and concentrated under 
reduced pressure.  The aliquot was used for TLC monitoring which showed reaction completion. The reaction 
was filtered through a funnel packed with Celite. The filter cake was washed with MeOH and the filtrate was 
concentrated under reduced pressure, to give S7 (553 mg) as a dark yellow oil in 94% yield. The material was 
pushed forward without purification. This compound has been previously reported and characterized 
(CAS#23079-68-7). TLC: mobile phase: EtOAc:hexanes (25:75), Rf: 0.55; 1H NMR (300 MHz,CDCl3) δ = 7.04 (t, J = 
8.0 Hz, 1 H), 6.38 - 6.21 (m, 3 H), 3.91 (t, J = 6.5 Hz, 2 H), 1.80 - 1.67 (m, 2 H), 1.47 (m, 2 H), 0.96 (t, J = 7.4 Hz, 3 
H).filled with H2 gas and inserted into the flask and the reaction was purged with H2 gas for 2 min. The reaction 
was left to stir under a full balloon of H2 for 1 h, after which an aliquot was taken from the reaction, filtered 
through celite and cotton, and concentrated under reduced pressure.  The aliquot was used for TLC monitoring 
which showed reaction completion. The reaction was filtered through a funnel packed with Celite. The filter 
cake was washed with MeOH and the filtrate was concentrated under reduced pressure, to give S7 (553 mg) as a 
dark yellow oil in 94% yield. The material was pushed forward without purification. This compound has been 
previously reported and characterized (CAS#23079-68-7). TLC: mobile phase: EtOAc:hexanes (25:75), Rf: 0.55; 
1H NMR (300 MHz,CDCl3) δ = 7.04 (t, J = 8.0 Hz, 1 H), 6.38 - 6.21 (m, 3 H), 3.91 (t, J = 6.5 Hz, 2 H), 1.80 - 1.67 (m, 




Analogue (24) was synthesized by coupling S7 with 2-bromobenzoyl chloride (956 mg, 4.35 mmol) according to 
general method C. The crude material was dissolved in a minimal amount of DCM, loaded onto a 50 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–30%) to give 24 as a white solid (138 mg) in 
12% yield. 1H NMR (400 MHz, CDCl3) δ = 7.69 - 7.63 (m, 2 H), 7.62 (br. s., 1 H), 7.46 - 7.38 (m, 2 H), 7.37 - 7.30 
(m, 1 H), 7.26 - 7.22 (m, 1 H), 7.10 - 7.04 (m, 1 H), 6.75 - 6.70 (m, 1 H), 4.00 (t, J = 6.5 Hz, 2 H), 1.83 - 1.73 (m, 2 




Analogue (25) was synthesized via a peptide coupling between S3 (50.0 mg, 0.172 mmol), and 2-
(dimethylamino)acetic acid (26.6 mg, 0.252 mmol) according to general method A. The crude material was 
dissolved in minimal DCM, loaded on to a 25 g silica column, and purified by flash chromatography 
(EtOAc:hexanes 0–100%) to give 25 as an off white solid in 44% yield. LC/MS tR = 1.68 min (Characterization 
Method A); m/z = 377.75 (M + H); 1H NMR (300 MHz, CDCl3) δ 7.99 (t, J = 1.9 Hz, 1H), 7.68 (dd, J = 7.9, 0.9 Hz, 




To a 50 mL round bottom flask was added a magnetic stir bar and 40 mg of 3 Å molecular sieves. Propanal (352 
µL, 4.91 mmol) was added to the round bottom flask alongside methanol (4 mL) and Acetic acid (14.1 µL, 0.246 
mmol). The vessel was sealed and flushed with nitrogen gas for 2 min and to this S3 was added into the flask. 
The mixture was cooled to 0°C and allowed to stir for 30 min before NaBH3CN (61.7 mg, 0.982 mmol) was 
added. The reaction was allowed to stir at 0°C and gradually allowed to warm up to room temperature for an 
additional 1 h. A sample aliquot was taken from the reaction, diluted with DCM, and washed with half saturated 
Na2CO3.  The organic layer was separated and analyzed with LCMS to confirm reaction completion. The reaction 
was diluted with DCM (10 mL), washed with half-saturated aq. NaHCO3 (2 x 15 mL), dried over Na2SO4, filtered, 
and concentrated under reduced pressure to give crude product. The crude product was dissolved in a minimal 
amount of DCM, loaded onto a 10 g silica column, and purified with flash chromatography (MeOH:DCM, 2–10%) 
to give amine 26 (96 mg) as a yellow oil in 59% yield. LC/MS tR = 5.24 min (Characterization Method A); m/z = 
375.90 (M + H); 1H NMR (400 MHz, CDCl3) δ =7.64 - 7.55 (m, 1 H), 7.42 - 7.23 (m, 1 H), 7.19 - 7.11 (m, 1 H), 6.74 
(d, J = 7.8 Hz, 0 H), 6.44 (dd, J = 2.2, 8.4 Hz, 0 H), 3.25 (t, J = 1.0 Hz, 2 H), 1.68 - 1.57 (m, 2 H), 0.93 (t, J = 7.4 Hz, 3 
H); 13C NMR (101 MHz, CDCl3) δ = 165.5, 148.9, 138.7, 138.2, 133.4, 131.4, 129.7, 129.6, 127.7, 119.3, 108.3, 




To a 50 mL round bottom flask was added aniline S3 (50 mg, 0.172 mmol), K2CO3 (48 mg, 0.343 mmol), and a 
magnetic stir bar. The flask was sealed and flushed with nitrogen gas for 5 min. The contents were dissolved in 
anhydrous DMF (5 mL) and then 1-bromo-2-methoxyethane (24 µL, 0.258 mmol) was added via syringe to the 
flask and stirred at 80 °C for 24 h. After 24 h, the reaction was diluted with EtOAc (30 mL), washed with half-
saturated aq. NaHCO3 (2 x 15 mL), dried over with Na2SO4, filtered, and concentrated under reduced pressure 
to give crude product. The crude product was dissolved in a minimal amount of DCM, loaded onto a 50 g silica 
column, and purified with flash chromatography (EtOAc:hexane, 0–65%) to give 27 (8 mg) as a yellow oil in 14% 
yield. 1H NMR (400MHz, CDCl3) δ = 7.67 - 7.62 (m, 2 H), 7.54 (br. s., 1 H), 7.42 (dt, J = 1.2, 7.6 Hz, 1 H), 7.36 - 
7.28 (m, 1 H), 7.22 (t, J = 2.2 Hz, 1 H), 7.16 (t, J =8.0 Hz, 1 H), 6.76 (dd, J = 1.2, 7.8 Hz, 1 H), 6.45 (dd, J = 1.8, 7.6 
Hz, 1 H), 3.62 (t, J = 5.1 Hz, 2 H), 3.40 (s, 3 H), 3.32 (t, J = 5.3 Hz, 2 H). 
 
 
3-{[(tert-butyldimethylsilyl)oxy]methyl}aniline (S8)  
3-aminobenzyl alcohol (1.20 g, 9.74 mmol) was added to a 100 mL round bottom flask with a magnetic stir bar, 
and then dissolved in anhydrous DMF (25 mL). To the solution was added TBDMSCl (1.73 g, 11.5 mmol), DMAP 
(0.03 g, 0.025 mmol), and TEA (1.63 mL, 11.7 mmol) and the reaction stir at room temperature for 24 h. A small 
aliquot of the reaction was taken and used for TLC monitoring, which showed consumption of starting material. 
The reaction was transferred to a separatory funnel and diluted with DI water and extracted with EtOAc (2x 125 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure 
to give crude product. The crude material was dissolved in a minimal amount of DCM, loaded onto a 100 g silica 
column, and purified by flash chromatography (EtOAc:hexanes, 0–50%) to give S8 as a clear liquid (2.1 g) in 91% 
yield. This compound has been previously reported and characterized (CAS#159217-95-5). TLC: mobile phase: 
EtOAc:hexanes (30:70), Rf: 0.64; 1H NMR (400 MHz, CDCl3) δ = 7.12 (t, J = 7.7 Hz, 1 H), 6.74 - 6.68 (m, 2 H), 6.58 




Aniline S8 (250 mg, 1.05 mmol) was added to a 100 mL round bottom flask with a magnetic stir bar, and then 
dissolved in anhydrous DCM (6 mL). The vessel was flushed with nitrogen for 5 min and to the suspension was 
added 2-bromobenzoic acid (240 mg, 1.19 mmol), TEA (0.31 mL, 2.21 mmol), and BOP-Cl (293 mg, 1.09 mmol). 
The reaction mixture stirred for 19 h at room temperature and then monitored by TLC which showed 
consumption of starting material. The reaction was diluted with EtOAc (30 mL) and washed with half-saturated 
aq. NaHCO3, 1M HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to 
give crude product. The crude material was passed through a silica plug using 5% MeOH:DCM to yield S9 as a 
clear yellow liquid (380mg) in 86% yield. TLC: mobile phase: EtOAc: hexanes (30:70), Rf: 0.66; 1H NMR (400 MHz 
, CDCl3) δ = 7.59 (br. s., 1 H), 7.35 - 7.21 (m, 4 H), 7.11 - 6.93 (m, 3 H), 6.84 (d, J = 7.6 Hz, 1 H), 4.45 (s, 2 H), 0.65 




To a 100 mL round bottom flask, S9 (300 mg, 0.714 mmol) was added alongside a magnetic stir bar and diluted 
with anhydrous THF (6 mL). To the stirring reaction, 1 M TBAF in THF (0.80 mL, 0.800 mmol) was added via 
syringe. The reaction was stirred at room temperature for 2 h before a sample aliquot was taken from the 
reaction, diluted with DCM, and washed with half saturated Na2CO3.  The organic layer was separated and 
analyzed with TLC to confirm reaction completion. The reaction was diluted with sat. ammonium chloride (25 
mL) and transferred to a separatory funnel and extracted with EtOAc (2 x 25mL). The organic layer was washed 
with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude product. The 
crude material was dissolved in a minimal amount of DCM, loaded onto a 10 g silica column, and purified by 
flash chromatography (EtOAc: hexanes, 20–100%) to give S10 as a white solid (164 mg) in 90% yield. TLC: mobile 
phase: EtOAc: hexanes (30:70), Rf: 0.23; 1H NMR (400 MHz, (CD3)2CO) δ = 9.49 (br. s., 1 H), 7.84 (s, 1 H), 7.72 - 
7.65 (m, 2 H), 7.57 (dd, J = 1.6, 7.6 Hz, 1 H), 7.48 (t, J = 7.5 Hz, 1 H), 7.43 - 7.36 (m, 1 H), 7.32 (t, J = 7.8 Hz, 1 H), 




To a 100 mL round bottom flask, alcohol S10 (105mg, 0.343 mmol) was added alongside a magnetic stir bar. The 
starting material was dissolved in DCM (6 mL) and DMP (382 mg, 0.901 mmol) was added with along with DI 
water (0.02 mL). The reaction was heated to 30 °C for 2.5 h and was then monitored by TLC which showed 
consumption of starting material.  The reaction was filtered through a funnel packed with Celite. The filter cake 
was washed with DCM and the filtrate was concentrated under reduced pressure, to give crude material. The 
crude material was dissolved in a minimal amount of DCM and loaded onto a 10 g silica column, and purified by 
flash chromatography (EtOAc:hexanes, 20–100%) to give S11 as a white solid (80 mg) in 77% yield. This 
compound has been previously reported and characterized (CAS#1968124-06-2). TLC: mobile phase: 
MeOH:DCM (4:96), Rf: 0.80; 1H NMR (400 MHz, CD3OD) δ = 9.99 (s, 1 H), 8.28 (t, J = 1.8 Hz, 1 H), 7.95 (ddd, J = 
1.1, 2.2, 8.1 Hz, 1 H), 7.74 - 7.66 (m, 2 H), 7.61 - 7.52 (m, 2 H), 7.48 (dt, J = 1.2, 7.5 Hz, 1 H), 7.43 - 7.35 (m, 1 H). 
 
 
2-bromo-N-{3-[(propylamino)methyl]phenyl}benzamide  (28) 
To a 100 mL round bottom flask was added a magnetic stir bar and 40 mg of 3 Å molecular sieves. Aldehyde S11 
(38.5 mg, 0.127 mmol) was added to the round bottom flask alongside DCE (4 mL) and acetic acid (170 µL, 0.297 
mmol). The vessel was sealed and flushed with nitrogen gas for 5 min and to this propylamine (250 µL, 0.304 
mmol) was syringed into the flask.  The mixture stirred at room temperature for 1 h before STAB (59.1 mg, 0.279 
mmol) was added, and the reaction was allowed to stir at room temperature for an additional 21 h. A sample 
aliquot was taken from the reaction, diluted with DCM, and washed with half saturated Na2CO3. The organic 
layer was separated and analyzed with TLC to confirm reaction completion. The reaction was diluted with DCM 
(10 mL), washed with half-saturated aq. NaHCO3 (2 x 15 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give crude product. The crude product was dissolved in a minimal amount of DCM, 
loaded onto a 10 g silica column, and purified with flash chromatography (MeOH:DCM, 2–16% to give amine 28 
(32 mg) as a clear oil in 73% yield. The product was converted to the HCl salt by adding 0.9 M HCl in ether (0.14 
mL) and lyophilizing overnight to give the HCl salt as an off-white solid. TLC: mobile phase: MeOH:DCM (10:90), 
Rf: 0.46; 1H NMR (300 MHz, D2O) δ = 7.58 - 7.33 (m, 2 H), 7.33 - 7.01 (m, 7 H), 4.61 (s, 2 H), 2.85 - 2.69 (m, 2 H), 




To a 50 mL round bottom flask was added a magnetic stir bar and 40 mg of 3 Å molecular sieves. 
cyclopentanone (988 µL, 11.2 mmol) was added to the round bottom flask alongside methanol (8 mL) and Acetic 
acid (32.0 µL, 0.558 mmol). The vessel was sealed and flushed with nitrogen gas for 2 min and to this S3 was 
added into the flask. The mixture was cooled to 0°C and allowed to stir for 30 min before NaBH3CN (140 mg, 
2.23 mmol) was added. The reaction was allowed to stir at 0°C and gradually allowed to warm up to room 
temperature for an additional 1 h. A sample aliquot was taken from the reaction, diluted with DCM, and washed 
with half saturated Na2CO3.  The organic layer was separated and analyzed with LCMS to confirm reaction 
completion. The reaction was diluted with DCM (10 mL), washed with half-saturated aq. NaHCO3 (2 x 15 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure to give crude product. The crude product 
was dissolved in a minimal amount of DCM, loaded onto a 10 g silica column, and purified with flash 
chromatography (EtOAc:hexanes, 10–60%) to give amine 29 (385 mg) as a yellow solid in 96% yield. LC/MS tR = 
5.24 min (Characterization Method A); m/z = 360.85 (M + H); 1H NMR (300 MHz, CDCl3) δ 7.75 (br. s., 1H), 7.57 
(ddd, J = 9.7, 7.7, 1.6 Hz, 2H), 7.35 (td, J = 7.5, 1.3 Hz, 1H), 7.31–7.23 (m, 1H), 7.17 (t, J = 2.0 Hz, 1H), 7.11 (t, J = 
8.0 Hz, 1H), 6.74 – 6.70 (m, 1H), 6.39 (ddd, J = 8.2, 2.3, 0.9 Hz, 1H), 3.83 – 3.73 (m, 1H), 2.16–1.92 (m, 4H), 1.74–
1.45 (m, 4H). 13C NMR (75 MHz, CDCl3) δ = 165.8, 149.1, 138.8, 138.3, 133.6, 131.7, 129.9, 127.9, 119.5, 109.7, 
108.5, 105.0, 54.8, 38.6, 33.8, 24.3, 23.5. 
 
 
2-bromo-N-[3-(pyrrolidin-1-yl)phenyl]benzamide KMK-17 (30) 
To a round bottom flask was added aniline S3 (264 mg, 0.908 mmol), K2CO3 (157 mg, 1.13 mmol), a cat. amount 
of KI (0.753 mg, 0.00454 mmol) and a magnetic stir bar. The flask was sealed and flushed with nitrogen gas for 5 
min. The contents were dissolved in anhydrous acetonitrile (10 mL) and then 1,4-dibromobutane (54 µL, 0.454 
mmol) was added via syringe to the flask and stirred at 50 °C for 30 min. After 30 min, a sample aliquot was 
taken from the reaction, concentrated under reduced pressure, dissolved in a minimal amount of HPLC grade 
MeCN, and analyzed with LCMS which showed no reaction. Toluene (10 mL) was introduced into the reaction 
and the reaction was heated to 90 °C for 24 h. A sample aliquot was taken from the reaction and analyzed with 
LCMS to show reaction completion. The reaction was diluted with EtOAc (30 mL), washed with half-saturated aq. 
NaHCO3 (2 x 15 mL), dried over with Na2SO4, filtered, and concentrated under reduced pressure to give crude 
product. The crude product was dissolved in a minimal amount of DCM, loaded onto a 10 g silica column, and 
purified with flash chromatography (EtOAc:hexane, 10–70% to give 30 (135 mg) as a yellow solid in 86% yield. 
LC/MS tR = 6.05 min (Characterization Method A); m/z = 346.85 (M + H); 1H NMR (300 MHz, CDCl3) δ =  7.63 (td, 
J = 1.8, 7.7 Hz, 2 H), 7.59 (br. s., 1 H), 7.39 (dt, J = 1.2, 7.5 Hz, 1 H), 7.36 - 7.27 (m, 1 H), 7.19 (t, J = 8.1 Hz, 1 H), 
7.03 (t, J = 2.0 Hz, 1 H), 6.79 (dd, J = 1.2, 7.9 Hz, 1 H), 6.38 (dd, J = 2.0, 8.1 Hz, 1 H), 3.37 - 3.26 (m, 4 H), 2.06 - 
1.94 (m, 4 H). 
 
 
tert-butyl (2R)-2-{[3-(2-bromobenzamido)phenyl]carbamoyl}pyrrolidine-1-carboxylate (31) 
Analogue (31) was synthesized by coupling S3 with Boc-D-proline (133 mg, 0.619 mmol) according to general 
method D. The crude material was dissolved in a minimal amount of DCM, loaded onto a 25 g silica column, and 
purified by flash chromatography (EtOAc:hexanes, 0–50%) to give 31 as a white solid (150 mg) in 74% yield. 
LC/MS tR = 5.70 min (Characterization Method A); m/z = 488.00 (M + H); 1H NMR (400 MHz, CD3OD) δ = 8.05 - 
7.95 (m, 1 H), 7.66 (d, J = 8.0 Hz, 1 H), 7.54 - 7.22 (m, 7 H), 4.36 - 4.22 (m, 1 H), 3.59 - 3.40 (m, 2 H), 2.35 - 2.20 
(m, 1 H), 2.03 (br s, 3 H), 1.88 (d, J = 6.8 Hz, 1 H), 1.45 (br s, 3 H), 1.37 (s, 7 H). 
 
 
(2R)-N-[3-(2-bromobenzamido)phenyl]pyrrolidine-2-carboxamide (32)  
To a 25 mL round bottom flask with a stir bar was added 31 (76 mg, 0.156  mmol) and anhydrous DCM (5 mL), 
which was subsequently flushed with nitrogen gas for 5 minutes. To the sealed flask, via syringe, was added 4 M 
HCl in dioxane (1.20 mL).  The reaction was allowed to stir at room temperature for 1 h. The reaction mixture 
was concentrated under reduced pressure (passed through a base trap) to give crude material that was 
suspended in EtOAc and washed with half-saturated aq. NaHCO3, and brine. The reaction was dried over 
Na2SO4, filtered, and concentrated under reduced pressure to give crude material. The crude material was 
dissolved in a minimal amount of DCM, loaded onto a 10 g silica column, and purified by flash chromatography 
(MeOH:DCM, 0-6%) to give 32 as a white solid (42 mg) in 69% yield. Note: after the purification the free-amine 
was converted to the HCl salt by introducing excess 4 M HCl in dioxane and subsequently removing the acid 
under reduced pressure (through a base trap). LC/MS tR = 2.59 min (Characterization Method A); m/z = 389.00 
(M + H); 1H NMR (400 MHz, CD3OD) δ = 8.00 (t, J = 2.0 Hz, 1 H), 7.69 - 7.63 (m, 1 H), 7.55 - 7.33 (m, 5 H), 7.33 - 
7.23 (m, 1 H), 3.83 (dd, J = 6.0, 8.7 Hz, 1 H), 3.14 - 2.94 (m, 2 H), 2.30 - 2.17 (m, 1 H), 1.95 - 1.76 (m, 3 H). 
 
 
tert-butyl (2S)-2-{[3-(2-bromobenzamido)phenyl]carbamoyl}pyrrolidine-1-carboxylate (33)  
Analogue (33) was synthesized by coupling S3 with Boc-L-proline (150 mg, 0.697 mmol) according to general 
method D. The crude material was dissolved in a minimal amount of DCM, loaded onto a 25 g silica column, and 
purified by flash chromatography (EtOAc:hexanes, 0–50%) to give 33 as a white solid (158 mg) in 70% yield. 
LC/MS tR = 5.69 min (Characterization Method A); m/z = 488.95 (M + H); 1H NMR (400 MHz, CD3OD) δ = 8.05 - 
7.95 (m, 1 H), 7.66 (d, J = 8.0 Hz, 1 H), 7.54 - 7.23 (m, 7 H), 4.37 - 4.20 (m, 1 H), 3.59 - 3.37 (m, 2 H), 2.36 - 2.19 
(m, 1 H), 2.05 - 1.93 (m, 3 H), 1.93 - 1.80 (m, 1 H), 1.45 (s, 3 H), 1.39 (s, 7 H). 
 
 
(2S)-N-[3-(2-bromobenzamido)phenyl]pyrrolidine-2-carboxamide (34)  
To a 25 mL round bottom flask with a stir bar was added 33 (36 mg, 0.074 mmol) and anhydrous DCM (5 mL), 
which was subsequently flushed with nitrogen gas for 5 minutes. To the sealed flask, via syringe, was added 4 M 
HCl in dioxane (1 mL).  The reaction was allowed to stir at room temperature for 1 h. The reaction mixture was 
concentrated under reduced pressure (passed through a base trap) to give crude material that was suspended in 
EtOAc and washed with half-saturated aq. NaHCO3, and brine. The reaction was dried over Na2SO4, filtered, 
and concentrated under reduced pressure to give crude material. The crude material was dissolved in a minimal 
amount of DCM, loaded onto a 10 g silica column, and purified by flash chromatography (MeOH:DCM, 0-6%) to 
give 34 as a white solid (22 mg) in 78% yield. Note: after the purification the free-amine was converted to the 
HCl salt by introducing excess 4 M HCl in dioxane and subsequently removing the acid under reduced pressure 
(through a base trap). LC/MS tR = 2.55 min (Characterization Method A); m/z = 389.85 (M + H); 1H NMR (300 
MHz, CD3OD) δ = 7.98 - 7.78 (m, 1 H), 7.65 - 7.44 (m, 5 H), 7.44 - 7.25 (m, 6 H), 6.91 (d, J = 7.6 Hz, 1 H), 4.03 (dd, 
J = 4.6, 9.5 Hz, 1 H), 3.20 - 2.92 (m, 1 H), 2.69 - 2.56 (m, 1 H), 2.29 - 2.16 (m, 1 H), 2.08 - 1.72 (m, 3 H). 
 
 
N-[3-(2-bromobenzamido)phenyl]furan-2-carboxamide (35)  
Analogue (25) was synthesized via a peptide coupling between S3 (50.0 mg, 0.172 mmol), and furan-2-carboxylic 
acid (19.6 mg, 0.172 mmol) according to general method A. The crude material was dissolved in minimal DCM, 
loaded on to a 10 g silica column, and purified by flash chromatography (MeOH:DCM 0–10%) to give 35 as an off 
white solid in 44% yield. TLC: mobile phase: MeOH:DCM (10:90), Rf: 0.85; LC/MS tR = 4.82 min (Characterization 
Method A); m/z = 386.75 (M + H); 1H NMR (300 MHz, CDCl3) δ 8.17 (br. s., 1H), 8.09 (s, 1H), 7.86 (br. s., 1H), 




N-[3-(2-bromobenzamido)phenyl]oxolane-2-carboxamide (36)  
Analogue (36) was synthesized by acylating S3 with tetrahydrofuran-2-carboxylic acid (41 µL, 0.431 mmol) 
according to general method B. The crude material was dissolved in a minimal amount of DCM, loaded onto a 10 
g silica column, and purified by flash chromatography (EtOAc:hexanes, 0–100%) to give 36 as a white solid (55 
mg) in 33% yield. LC/MS tR = 5.22 min (Characterization Method A); m/z = 413.05 (M + Na); 1H NMR (300 MHz, 
CDCl3) δ = 8.54 (s, 1 H), 7.98 (t, J = 1.9 Hz, 1 H), 7.89 (br. s., 1 H), 7.67 - 7.55 (m, 2 H), 7.48 - 7.27 (m, 5 H), 4.41 
(dd, J = 5.9, 8.3 Hz, 1 H), 4.11 - 3.87 (m, 2 H), 2.42 - 2.25 (m, 1 H), 2.21 - 2.06 (m, 1 H), 2.02 - 1.85 (m, 2 H). 
 
 
N-[3-(2-bromobenzamido)phenyl]oxolane-3-carboxamide (37)  
Analogue (37) was synthesized by acylating S3 with tetrahydrofuran-3-carboxylic acid (41 µL, 0.431 mmol) 
according to general method B. The crude material was dissolved in a minimal amount of DCM, loaded onto a 10 
g silica column, and purified by flash chromatography (EtOAc:hexanes, 0–100%) to give 37 as a white solid (32 
mg) in 19% yield. LC/MS tR = 5.22 min (Characterization Method B); m/z = 387.05 (M + H); 1H NMR (400 MHz, 
(CD3)2SO) δ = 10.09 (br. s., 1 H), 8.08 (s, 1 H), 7.70 (d, J = 7.7 Hz, 1 H), 7.55 - 7.45 (m, 2 H), 7.44 - 7.35 (m, 2 H), 
7.33 - 7.18 (m, 2 H), 3.92 (t, J = 8.2 Hz, 1 H), 3.81 - 3.63 (m, 3 H), 3.21 - 3.07 (m, 1 H), 2.13 - 1.97 (m, 2 H). 
 
 
N-[3-(2-bromobenzamido)phenyl]-1,3-oxazole-4-carboxamide (39)  
Analogue (39) was synthesized by acylating S3 with oxazole-4-carboxylic acid (19.7 mg, 0.174 mmol) according 
to general method A. The crude material was dissolved in a minimal amount of DCM, loaded onto a 5 g silica 
column, and purified by flash chromatography (MeOH:DCM, 0–8%) to give 39 as a yellow oil (19 mg) in 29% 
yield. LC/MS tR = 4.56 min (Characterization Method A); m/z = 387.05 (M + H); 1H NMR (300 MHz, (CD3)2CO) δ 
= 9.50 (d, J = 1.0 Hz, 1 H), 8.58 (d, J = 1.0 Hz, 1 H), 8.40 - 8.30 (m, 2 H), 7.73 - 7.55 (m, 5 H), 7.55 - 7.30 (m, 4 H). 
 
 
N-(3-benzamidophenyl)-2-bromobenzamide (40)  
Analogue (40) was synthesized by acylating S3 with benzoyl chloride (29.1 mg, 0.207 mmol) according to general 
method A. The crude material was dissolved in a minimal amount of DCM, loaded onto a 5 g silica column, and 
purified by flash chromatography (MeOH:DCM, 0–8%) to give 40 as a yellow oil (32 mg) in 46% yield. LC/MS tR = 
5.23 min (Characterization Method A); m/z = 396.75 (M + H); 1H NMR (300 MHz, CD3OD) δ = 8.14 (t, J = 1.9 Hz, 1 
H), 7.96 - 7.89 (m, 2 H), 7.68 (dd, J = 0.8, 7.9 Hz, 1 H), 7.62 - 7.42 (m, 7 H), 7.41 - 7.30 (m, 2 H). 
 
4. Compound characterization data 
 
LC/MS (+ mode) for compound 3 
 
 
S-30LC/MS (+ mode) for compound 5 
 
 
LC/MS (+ mode) for compound 6 
 
LC/MS (- mode) for compound 7 
 
 
1H NMR (400 MHz, (CD3)2CO) of compound 7 
 
 
LC/MS (+ mode) for compound 8 
 
 
LC/MS (+ mode) for compound 9 
 
 
1H NMR (400 MHz, CD3OD) of compound 9 
 
 
LC/MS (+ mode) for compound 10 
 
 
LC/MS (+ mode) for compound 11 
 
 
LC/MS (+ mode) for compound 12 
 
 
1H NMR (400 MHz, CD3OD) of compound 12 
 
 
LC/MS (+ mode) for compound 13 
 
 
1H NMR (300 MHz, CD3OD) of compound 13 
 
 
LC/MS (+ mode) for compound 14 
 
 
1H NMR (300 MHz, CD3OD) of compound 14 
 
 
LC/MS (+ mode) for compound 15 
 
 
1H NMR (300 MHz, CDCl3) of compound 15 
 
 
LC/MS (+ mode) for compound 16 
 
 
1H NMR (300 MHz, CD3OD) of compound 16 
 
 
LC/MS (+ mode) for compound 17 
 
 
1H NMR (300 MHz, CDCl3) of compound 15 
 
 
LC/MS (+ mode) for compound 18 
 
 
1H NMR (400 MHz, CDCl3) of compound 18 
 
 
1H NMR (300 MHz, CDCl3) of compound 19 
 
 
1H NMR (300 MHz, CD3OD) of compound 20 
 
 
1H NMR (300 MHz, CD3OD) of compound 21 
 
 
LC/MS (+ mode) for compound 22 
 
 
1H NMR (400 MHz, CD3OD) of compound 22 
 
 
LC/MS (+ mode) for compound 23 
 
 
1H NMR (300 MHz, CDCl3) of compound 23 
 
 
1H NMR (400 MHz, CDCl3) of compound S6 
 
 
1H NMR (400 MHz, CDCl3) of compound S7 
 
 
1H NMR (400 MHz, CDCl3) of compound 24 
 
 
LC/MS (+ mode) for compound 25 
 
 
1H NMR (300 MHz, CDCl3) of compound 25 
 
 
LC/MS (+ mode) for compound 26 
 
 
13C NMR (101 MHz, CDCl3) of compound 26 
 
 
1H NMR (400 MHz, CDCl3) of compound 27 
 
 
1H NMR (400 MHz, CDCl3) of compound S8 
 
 
1H NMR (400 MHz, CDCl3) of compound S9 
 
 
1H NMR (400 MHz, (CD3)2CO) of compound S10 
 
 
1H NMR (400 MHz, CD3OD) of compound S11 
 
 
LC/MS (+ mode) for compound 28 
 
 
1H NMR (300 MHz, D2O) of compound 28 
 
 
LC/MS (+ mode) for compound 29 
 
 
1H NMR (300 MHz, CDCl3) of compound 29 
 
 
13C NMR (75 MHz, CDCl3) of compound 29 
 
 
LC/MS (+ mode) for compound 30 
 
 
1H NMR (300 MHz, CDCl3) of compound 30 
 
 
LC/MS (+ mode) for compound 31 
 
 
1H NMR (400 MHz, CD3OD) of compound 31 
 
 
LC/MS (+ mode) for compound 32 
 
 
1H NMR (400 MHz, CD3OD) of compound 32 
 
 
LC/MS (+ mode) for compound 33 
 
 
1H NMR (400 MHz, CD3OD) of compound 33 
 
 
LC/MS (+ mode) for compound 34 
 
 
1H NMR (300 MHz, CDCl3) of compound 34 
 
 
LC/MS (+ mode) for compound 35 
 
 
1H NMR (300 MHz, CDCl3) of compound 35 
 
 
LC/MS (+ mode) for compound 36 
 
 
1H NMR (300 MHz, CDCl3) of compound 36 
 
 
LC/MS (+ mode) for compound 37 
 
 
1H NMR (300 MHz, (CD3)2SO) of compound 37 
 
 
LC/MS (+ mode) for compound 38 
 
 
1H NMR (300 MHz, CD3OD) of compound 38 
 
 
13C NMR (75 MHz, CD3OD) of compound 38 
 
 
LC/MS (+ mode) for compound 39 
 
 
1H NMR (300 MHz, (CD3)2CO) of compound 39 
 
 
LC/MS (+ mode) for compound 40 
 
 
1H NMR (300 MHz, (CD3OD) of compound 40 
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